CAS |
42017-89-0 |
Chinese Name |
非诺贝特酸 |
English Name |
Fenofibric Acid |
Synonym |
NSC 281318;Trilipix;FNF acid |
Purity |
≥98% |
Unit |
Bottle |
Molecular Formula |
C17H15ClO4 |
Molecular Weight |
318.75 |
Appearance |
White to off-white solid |
Storage |
Powder : 2-8℃, 2 years; In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO≥5mg/ml(Need ultrasonic) |
MDL |
MFCD00792461 |
EC |
EINECS 255-626-9 |
InChIKey |
MQOBSOSZFYZQOK-UHFFFAOYSA-N |
InChI |
InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21) |
PubChem CID |
64929 |
SMILES |
CC(C)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C(O)=O |
Description |
Fenofibric Acid is a PPAR agonist; also inhibits COX-2 activity. |
Target Point |
PPAR,COX2 |
Passage |
Cell Cycle;DNA Damage/DNA Repair;Metabolic Enzyme&Protease;Immunology & Inflammation; |
Data Literature Source |
[1]. Dietz M, et al. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem. 2012 Jun;7(6):1101-11.
[2]. Prasad GS, et al. Anti-inflammatory activity of anti-hyperlipidemic drug, fenofibrate, and its phase-I metabolite fenofibric acid: in silico, in vitro, and in vivo studies. Inflammopharmacology. 2017 Dec 13.
[3]. Neumeier M, et al. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem Biophys Res Commun. 2006 Nov 24;350(3):731-5. Epub 2006 Sep 27.
[4]. Miranda S, et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. J Cell Physiol. 2012 Jun;227(6):2352-62 |
Specification |
250mg 500mg 1g |